Technical Analysis for KNSA - Kiniksa Pharmaceuticals, Ltd.

Grade Last Price % Change Price Change
grade F 5.24 -0.95% -0.05
KNSA closed down 0.95 percent on Friday, October 18, 2019, on 7.97 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical KNSA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -0.95%
Volume Surge Other -0.95%

Older signals for KNSA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
KNSA Chart by TradingView
Basic chart:
Profile
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.
Biotechnology Health Biopharmaceutical Pharmaceutical Industry Diseases Medication Pharmaceutical Industry In China Pharmacology
Is KNSA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 9 The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
Oct 8 Kiniksa Pharmaceuticals Enters Oversold Territory
Oct 4 The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
Oct 3 Stocks That Hit 52-Week Lows On Thursday
Sep 26 The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J
Sep 25 Stocks That Hit 52-Week Lows On Wednesday
Sep 24 Kiniksa Pharmaceuticals: Interesting, But No Catalyst Ahead
Sep 20 The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
Sep 19 Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research
Aug 19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
See more KNSA news...
Indicators
Indicator Value
52 Week High 28.9
52 Week Low 5.01
Average Volume 109,978
200-Day Moving Average 14.5096
50-Day Moving Average 8.6194
20-Day Moving Average 7.129
10-Day Moving Average 6.13
Average True Range 0.5423
ADX 46.31
+DI 6.8261
-DI 41.9183
Chandelier Exit (Long, 3 ATRs ) 7.823099999999999
Chandelier Exit (Short, 3 ATRs ) 6.6369
Upper Bollinger Band 9.4121
Lower Bollinger Band 4.8459
Percent B (%b) 0.09
BandWidth 64.051059
MACD Line -1.0065
MACD Signal Line -0.8675
MACD Histogram -0.1391
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.84
Resistance 3 (R3) 5.86 5.67 5.74
Resistance 2 (R2) 5.67 5.52 5.67 5.71
Resistance 1 (R1) 5.46 5.43 5.37 5.44 5.67
Pivot Point 5.27 5.27 5.23 5.27 5.27
Support 1 (S1) 5.06 5.12 4.97 5.04 4.81
Support 2 (S2) 4.87 5.03 4.87 4.77
Support 3 (S3) 4.66 4.87 4.74
Support 4 (S4) 4.64